Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

tion with InterMune's buyout of future royalties and milestones that would have been due under the previous license agreement with Marnac, Inc. and co-licensor KDL GmbH for the development and commercialization of pirfenidone.

As of December 31, 2007, InterMune had cash, cash equivalents and available-for-sale securities of approximately $235.3 million, compared with $214.5 million at December 31, 2006.

In October 2007, Targanta Therapeutics completed an initial public offering of its common stock, which resulted in the conversion of InterMune's interest in Targanta into approximately 3.0 million shares of Targanta common stock. As of December 31, 2007, InterMune recorded an unrealized gain of $5.7 million on 630,000 of those shares. The 630,000 shares met the criteria to be classified, as available-for-sale, marketable equity securities as they are estimated to qualify for sale within one year.

Dan Welch, President and Chief Executive Officer of InterMune, said, "The fourth quarter was a period of significant progress for InterMune. During the quarter, we significantly improved the potential economics of pirfenidone by eliminating all future royalties and milestones associated with a previous license and we acquired additional pirfenidone intellectual property that we believe will extend the exclusivity period for pirfenidone.

Mr. Welch continued, "We also recently completed the first two dose cohorts in the important Phase 1b study of ITMN-191, our first experience with the compound in patients chronically infected with the hepatitis C virus, and recently announced that we are planning to advance ITMN-191 to a 14-day triple combination study with Pegasus(R) and ribavirin. We look forward to the next 12 months as a pivotal period for InterMune, during which we expect to report the Phase 1b data on ITMN-191, execute a 14-day triple combination study of ITMN-191 and report the results from the Phase 3 CAPACITY program for pirfenidone." '/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... NEWTON, Mass., Aug. 11 Microfluidics International Corporation (OTC Bulletin ... June 30, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO ... , , Achieved positive earnings before ... Delivered strong bookings of $6.6 million with a backlog ...
... , BEIJING, Aug. 11 /PRNewswire-Asia/ -- ... provider of vaccines in China, today announced,that it will host ... a.m.,ET to review the Company,s second quarter financial results for ... recent corporate developments. , To access ...
... , , WALTHAM, Mass., Aug. ... advisory firms for pharmaceutical and healthcare issues, finds that the entry ... drug market to more than quadruple from approximately $420 million in ... The new Pharmacor report entitled Systemic Lupus Erythematosus ...
Cached Biology Technology:Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 9Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 2Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... work toward making genetically altered bacteria create living "circuits" ... they have logically assumed that the single-celled organisms would ... way. Alas, some bacteria apparently have an individualistic ... A new set of experiments by Duke University ...
... / b3c newswire / - KINAXO Biotechnologies GmbH ... service portfolio. KinAffinity provides invaluable information about a ... of interest. It simultaneously determines affinities for native ... overcomes the limitations of traditional biochemical assays that ...
... 2, 2009 Case Western Reserve University School of Medicine ... Maricich, M.D., Ph.D., and his team found that Merkel ... lineage, as previously speculated. The study, "Mammalian ... recently published in the online version of Developmental ...
Cached Biology News:Understanding a cell's split personality aids synthetic circuits 2Understanding a cell's split personality aids synthetic circuits 3KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2Case Western Reserve University discovers Merkel cell originates from skin, not the neural crest 2